Author Index

Search or browse for an author across our entire electronic archive

Search results for: G
Results 91 - 100 of 1441 shown below

  • Gallagher, C

    C Gallagher

    Oncology - An Oxford Core Text

    doi:10.1038/sj.bjc.6600293

    Abstract | Full article | PDF

  • Gallagher, C J

    S Slater, J Shamash, P Wilson, C J Gallagher and M L Slevin

    Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen

    doi:10.1038/sj.bjc.6600553

    Abstract | Full article | PDF

  • M Bhattacharyya, D Ryan, R Carpenter, S Vinnicombe and C J Gallagher

    Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer

    advance online publication, 2008-01-22 00:00:00.000;

    doi:10.1038/sj.bjc.6604171

    Abstract | Full article | PDF

  • J Shamash, R T D Oliver, C J Gallagher, A C Newland, T A Lister, S Kelsey, R K Gupta and C A O'Doherty

    Pre-induction LDH as a prognostic factor for outcome of high dose chemotherapy (HDCT) for germ cell tumours relapsing or refractory to conventional chemotherapy

    doi:10.1054/bjoc.1999.1140

    Abstract | Full article | PDF

  • C Mulatero, B R McClaren, M Mason, R T D Oliver and C J Gallagher

    Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma

    doi:10.1054/bjoc.2000.1480

    Abstract | Full article | PDF

  • Gallagher, E

    O Mc Cormack, W Y Chung, P Fitzpatrick, F Cooke, B Flynn, M Harrison, E Fox, E Gallagher, A Mc Goldrick, P A Dervan, A Mc Cann and M J Kerin

    Growth arrest-specific gene 6 expression in human breast cancer

    advance online publication, 2008-02-19 00:00:00.000;

    doi:10.1038/sj.bjc.6604260

    Abstract | Full article | PDF

  • Gallagher, J T

    A C Backen, C L Cole, S C Lau, A R Clamp, R McVey, J T Gallagher and G C Jayson

    Heparan sulphate synthetic and editing enzymes in ovarian cancer

    advance online publication, 2007-04-17 00:00:00.000;

    doi:10.1038/sj.bjc.6603747

    Abstract | Full article | PDF

  • Gallagher, R

    R Gallagher, C M Hughes, M M Murray, O P Friery, L H Patterson, D G Hirst and S R McKeown

    The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N

    doi:10.1038/sj.bjc.6600561

    Abstract | Full article | PDF

  • A Seaton, P J Maxwell, A Hill, R Gallagher, J Pettigrew, R H Wilson and D J J Waugh

    Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells

    advance online publication, 2009-10-06 00:00:00.000;

    doi:10.1038/sj.bjc.6605356

    Abstract | Full article | PDF

  • O P Friery, R Gallagher, M M Murray, C M Hughes, E S Galligan, I A McIntyre, L H Patterson, D G Hirst and S R McKeown

    Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine

    doi:10.1054/bjoc.1999.1132

    Abstract | Full article | PDF

  • R Gallagher, C M Hughes, M M Murray, O P Friery, L H Patterson, D G Hirst and S R McKeown

    The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N

    doi:10.1054/bjoc.2001.1975

    Abstract | Full article | PDF

  • Gallagher, R P

    M R Karagas, T A Stukel, J Dykes, J Miglionico, M A Greene, M Carey, B Armstrong, J M Elwood, R P Gallagher, A Green, E A Holly, C S Kirkpatrick, T Mack, A Østerlind, S Rosso and A J Swerdlow

    A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use

    doi:10.1038/sj.bjc.6600196

    Abstract | Full article | PDF

  • Gallagher, W M

    L M Greene, W O Twal, M J Duffy, E W McDermott, A D Hill, N J O'Higgins, A H McCann, P A Dervan, W S Argraves and W M Gallagher

    Elevated expression and altered processing of fibulin-1 protein in human breast cancer

    doi:10.1038/sj.bjc.6600802

    Abstract | Full article | PDF

  • W M Gallagher, L T Allen, C O'Shea, T Kenna, M Hall, A Gorman, J Killoran and D F O'Shea

    A potent nonporphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxia

    advance online publication, 2005-04-19 00:00:00.000;

    doi:10.1038/sj.bjc.6602527

    Abstract | Full article | PDF

  • A T Byrne, A E O'Connor, M Hall, J Murtagh, K O'Neill, K M Curran, K Mongrain, J A Rousseau, R Lecomte, S McGee, J J Callanan, D F O'Shea and W M Gallagher

    Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment

    advance online publication, 2009-10-13 00:00:00.000;

    doi:10.1038/sj.bjc.6605247

    Abstract | Full article | PDF

  • Gallamini, A

    G Todeschini, S Secchi, E Morra, U Vitolo, E Orlandi, F Pasini, E Gallo, A Ambrosetti, C Tecchio, C Tarella, A Gabbas, A Gallamini, L Gargantini, M Pizzuti, G Fioritoni, L Gottin, G Rossi, M Lazzarino, F Menestrina, M Paulli, M Palestro, M G Cabras, F Di Vito and G Pizzolo

    Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B

    doi:10.1038/sj.bjc.6601460

    Abstract | Full article | PDF

  • Gallardo, E

    J Carles, A Font, B Mellado, M Domenech, E Gallardo, J L González-Larriba, G Catalan, J Alfaro, A Gonzalez del Alba, M Nogué, P Lianes and J M Tello

    Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study

    advance online publication, 2007-10-23 00:00:00.000;

    doi:10.1038/sj.bjc.6604030

    Abstract | Full article | PDF

  • B Mellado, A Font, A Alcaraz, L A Aparicio, F J G Veiga, J Areal, E Gallardo, N Hannaoui, J R M Lorenzo, A Sousa, P L Fernandez and P Gascon

    Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer

    advance online publication, 2009-09-15 00:00:00.000;

    doi:10.1038/sj.bjc.6605320

    Abstract | Full article | PDF

  • Galle, P R

    M Moehler, A Eimermacher, J Siebler, T Höhler, A Wein, M Menges, D Flieger, T Junginger, T Geer, E Gracien, P R Galle and M Heike

    Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer

    advance online publication, 2005-06-07 00:00:00.000;

    doi:10.1038/sj.bjc.6602649

    Abstract | Full article | PDF

  • A Eickhoff, W Martin, D Hartmann, J C Eickhoff, M Möhler, P R Galle, J F Riemann and R Jakobs

    A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma

    advance online publication, 2006-05-23 00:00:00.000;

    doi:10.1038/sj.bjc.6603174

    Abstract | Full article | PDF

  • C C Schimanski, R Bahre, I Gockel, A Müller, K Frerichs, V Hörner, A Teufel, N Simiantonaki, S Biesterfeld, T Wehler, M Schuler, T Achenbach, T Junginger, P R Galle and M Moehler

    Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4

    advance online publication, 2006-07-04 00:00:00.000;

    doi:10.1038/sj.bjc.6603251

    Abstract | Full article | PDF